Form 4: Tyra Biosciences Executive Acquires 260,000 Stock Options
SEC Form 4 Filing
Douglas J. Warner, Chief Medical Officer of Tyra Biosciences, acquired 260,000 stock options on September 9, 2024.
Summary
- Douglas J. Warner, the Chief Medical Officer of Tyra Biosciences, acquired 260,000 stock options on September 9, 2024.
- The exercise price of these options is $21.51.
- The options vest over time, with 25% vesting on September 9, 2025, and the remainder vesting monthly thereafter, contingent upon continuous service to the Issuer.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It simply reports a transaction and doesn't convey any positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a common practice of granting stock options to company executives as part of their compensation package. It's typical for vesting schedules to be tied to continued employment.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the biotechnology industry.
- Vesting schedules, such as the one described (25% after one year, then monthly), are typical to incentivize long-term commitment.
- Comparing the size of the grant and the exercise price to those of executives at comparable biotech companies (e.g., Arcus Biosciences, Blueprint Medicines) would provide further context on the competitiveness of the compensation package.
Stakeholder Impact
- The granting of stock options to executives can align their interests with those of shareholders, as they benefit from increases in the company's stock price.
- Employees may view executive compensation packages as a reflection of the company's overall performance and commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 09/09/2024 | Date of transaction: Douglas J. Warner acquired 260,000 stock options. |
| 09/09/2025 | 25% of the stock options vest. |
| 09/08/2034 | Expiration date of the stock options. |
| 09/10/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.